DiscoverBridges - Advances in Cancer TherapeuticsEpisode 3 - Managing novel DLBCL therapies in the community - what good looks like
Episode 3 - Managing novel DLBCL therapies in the community - what good looks like

Episode 3 - Managing novel DLBCL therapies in the community - what good looks like

Update: 2025-11-24
Share

Description

Integrating novel therapies like bispecific antibodies (BsAbs) and antibody drug conjugates (ADCs) into community oncology practices can be a complex process. On this episode of Bridges, Dr. Lunning and Dr. Graff speak with Dr. Iqra Choudary about how she integrated BsAbs and ADCs into her practice with a proactive multidisciplinary team, strong safety protocols, comprehensive staff training, and strategic hospital partnerships.
 
Co-hosts: Dr. Matthew Lunning, MD, University of Nebraska Medical Center, and Dr. Tara Graff, MD, Mission Cancer & Blood
Guest: Dr. Iqra Choudary, board certified in Internal Medicine, Hematology-Oncology Associates of Central New York

Comments 
loading
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Episode 3 - Managing novel DLBCL therapies in the community - what good looks like

Episode 3 - Managing novel DLBCL therapies in the community - what good looks like

ADC Therapeutics